The company is incorporated as Apotheca Therapeutics, Inc.
Actuate forms a Scientific Advisory Board.
Food and Drug Administration grants 9-ING-41 an orphan drug designation for the treatment of glioblastoma.
Actuate technologies are featured in the Molecular Pathways section of the journal Clinical Cancer Research.
FDA grants 9-ING-41 an additional orphan drug designation for the treatment of neuroblastoma.
The FDA accepts Actuate’s IND application for 9-ING-41 with clearance to proceed with clinical study in patients with advanced cancers.
Actuate treats first patient in Phase 1 / 2 Clinical Study of 9-ING-41 in patients with refractory cancers.
Actuate announces initiation of Phase 2 clinical study in pancreatic cancer.
Actuate announces FDA fast track designation for 9-ING-41 in the treatment of pancreatic cancer.
Actuate announces the primary endpoint was met in the 9-ING-41 Phase 2 study in pancreatic cancer.
Actuate announces of a multicenter randomized trial for elraglusib plus FOLFIRONOX as first line therapy for advanced pancreatic cancer.